Literature DB >> 18829028

Plasma asymmetric dimethylarginine, L-arginine and left ventricular structure and function in a community-based sample.

Wolfgang Lieb1, Ralf A Benndorf, Emelia J Benjamin, Lisa M Sullivan, Renke Maas, Vanessa Xanthakis, Edzard Schwedhelm, Jayashri Aragam, Friedrich Schulze, Rainer H Böger, Ramachandran S Vasan.   

Abstract

OBJECTIVE: Increasing evidence indicates that cardiac structure and function are modulated by the nitric oxide (NO) system. Elevated plasma concentrations of asymmetric dimethylarginine (ADMA; a competitive inhibitor of NO synthase) have been reported in patients with end-stage renal disease. It is unclear if circulating ADMA and L-arginine levels are related to cardiac structure and function in the general population.
METHODS: We related plasma ADMA and L-arginine (the amino acid precursor of NO) to echocardiographic left ventricular (LV) mass, left atrial (LA) size and fractional shortening (FS) using multivariable linear regression analyses in 1919 Framingham Offspring Study participants (mean age 57 years, 58% women).
RESULTS: Overall, neither ADMA or L-arginine, nor their ratio was associated with LV mass, LA size and FS in multivariable models (p>0.10 for all). However, we observed effect modification by obesity of the relations of ADMA and LA size (p for interaction p=0.04): ADMA was positively related to LA size in obese individuals (adjusted-p=0.0004 for trend across ADMA quartiles) but not in non-obese people.
CONCLUSION: In our large community-based sample, plasma ADMA and l-arginine concentrations were not related to cardiac structure or function. The observation of positive relations of LA size and ADMA in obese individuals warrants confirmation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829028      PMCID: PMC2714984          DOI: 10.1016/j.atherosclerosis.2008.08.018

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  34 in total

1.  Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level.

Authors:  Jun-Lin Jiang; Hui-Qing Zhu; Zhou Chen; Hai-Yuan Xu; Yuan-Jian Li
Journal:  Int J Cardiol       Date:  2005-05-11       Impact factor: 4.164

2.  Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.

Authors:  Renate Schnabel; Stefan Blankenberg; Edith Lubos; Karl J Lackner; Hans J Rupprecht; Christine Espinola-Klein; Nicole Jachmann; Felix Post; Dirk Peetz; Christoph Bickel; François Cambien; Laurence Tiret; Thomas Münzel
Journal:  Circ Res       Date:  2005-08-11       Impact factor: 17.367

Review 3.  Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.

Authors:  Rainer H Böger
Journal:  Ann Med       Date:  2006       Impact factor: 4.709

Review 4.  Nitric oxide and the heart: update on new paradigms.

Authors:  C Belge; Paul B Massion; M Pelat; J L Balligand
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

Review 5.  L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor.

Authors:  Rainer H Böger; Eyal S Ron
Journal:  Altern Med Rev       Date:  2005-03

6.  Left atrial size in hypertensive men: influence of obesity, race and age. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

Authors:  J S Gottdiener; D J Reda; D W Williams; B J Materson
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

7.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

8.  Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.

Authors:  Hilde M A Eid; Harald Arnesen; Elsa M Hjerkinn; Torstein Lyberg; Ingebjørg Seljeflot
Journal:  Metabolism       Date:  2004-12       Impact factor: 8.694

9.  Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: the Strong Heart Study (SHS).

Authors:  Jorge R Kizer; Jonathan N Bella; Vittorio Palmieri; Jennifer E Liu; Lyle G Best; Elisa T Lee; Mary J Roman; Richard B Devereux
Journal:  Am Heart J       Date:  2006-02       Impact factor: 4.749

Review 10.  Cardiomyocyte-specific overexpression of nitric oxide synthase 3: impact on left ventricular function and myocardial infarction.

Authors:  Kenneth D Bloch; Stefan Janssens
Journal:  Trends Cardiovasc Med       Date:  2005-10       Impact factor: 6.677

View more
  3 in total

Review 1.  Translating metabolomics to cardiovascular biomarkers.

Authors:  Todd Senn; Stanley L Hazen; W H Wilson Tang
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

2.  Asymmetric dimethylarginine, related arginine derivatives, and incident atrial fibrillation.

Authors:  Renate B Schnabel; Renke Maas; Na Wang; Xiaoyan Yin; Martin G Larson; Daniel Levy; Patrick T Ellinor; Steven A Lubitz; David D McManus; Jared W Magnani; Dorothee Atzler; Rainer H Böger; Edzard Schwedhelm; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-03-17       Impact factor: 4.749

3.  Increased left atrial size in obese children and its association with insulin resistance: a pilot study.

Authors:  M L Marcovecchio; M Gravina; S Gallina; E D'Adamo; R De Caterina; F Chiarelli; A Mohn; G Renda
Journal:  Eur J Pediatr       Date:  2015-08-15       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.